This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hill, J. M. Articles by Bartunek, J. Search for Related Content PubMed PubMed Citation Articles by Hill, J. M. Articles by Bartunek, J. Related Collections Acute myocardial infarction

(Circulation. 2006;113:1926-1928.)
© 2006 American Heart Association, Inc.

Editorial

The End of Granulocyte Colony-Stimulating Factor in Acute Myocardial Infarction?

Reaping the Benefits Beyond Cytokine Mobilization

Jonathan M. Hill, MA, MBChB, MRCP; Jozef Bartunek, MD, PhD

From the Cardiovascular Division (J.M.H.), King’s College, London, United Kingdom, and Cardiovascular Center and Cardiovascular Research Center (J.B.), OLV Hospital, Aalst, Belgium.

Correspondence to Jonathan Hill, Clinical Senior Lecturer and Consultant Cardiologist, King’s College London, Cardiovascular Division, Bessemer Rd, London SE5 9PJ, United Kingdom. E-mail Jonathan.Hill@kcl.ac.uk

Key Words: Editorials • cells • myocardial infarction

An extract of the first 250 words of the full text is provided, because this article has no abstract.

"Perfect as the wing of a bird may be, it will never enable the bird to fly if unsupported by the air. Facts are the air of science. Without them a man of science can never rise."

— —Ivan Pavlov

Facts must be sought from the rigorous application of scientific method. Indeed, the hardest questions sometimes require the hardest methods. Having a tool that can answer the questions with the minimum number of side effects in the minimum number of patients must be the desire of all clinical investigators who wish to generate new facts and contribute to the pool of knowledge. Progress in cell therapy for cardiovascular disease has been hindered at both the preclinical and clinical stages, perhaps because the appropriate tools to address the pertinent questions have not been used. In this context, magnetic resonance imaging (MRI) has, by necessity, rapidly evolved as the ideal tool for surrogate end-point measurements in early-phase clinical trials. In this issue of Circulation, Ripa and colleagues¹ have elegantly demonstrated the utility and maturation of this technology in their study of granulocyte colony-stimulating factor (G-CSF) as an adjunctive therapy to mechanical reperfusion after myocardial infarction.

Article p 1983

Cardiovascular cell transplantation and cytokine mobilization originally began in clinical trials with the explicit goal of myocardial regeneration,^2,3 but more recently, the emphasis has been focused on "remodeling attenuation" therapy, in which the presumed mechanism has shifted from the "replacement" capacity of transplanted cells to their "paracrine" effects.⁴ This thesis becomes more convincing . . . [Full Text of this Article]

This article has been cited by other articles:

				W. Wojakowski, M. Kucia, K. Milewski, B. Machalinski, M. Halasa, P. Buszman, P. Klimeczek, M. Kazmierski, M. Pasowicz, M. Z. Ratajczak, et al. The role of CXCR4/SDF-1, CD117/SCF, and c-met/HGF chemokine signalling in the mobilization of progenitor cells and the parameters of the left ventricular function, remodelling, and myocardial perfusion following acute myocardial infarction Eur. Heart J. Suppl., December 1, 2008; 10(suppl_K): K16 - K23. [Abstract] [Full Text] [PDF]

				G. Ndrepepa, J. Mehilli, S. Martinoff, M. Schwaiger, A. Schomig, and A. Kastrati Evolution of Left Ventricular Ejection Fraction and its Relationship to Infarct Size After Acute Myocardial Infarction J. Am. Coll. Cardiol., July 10, 2007; 50(2): 149 - 156. [Abstract] [Full Text] [PDF]